BioNTech and OncoC4 Present Updated Data Showing Gotistobart Nearly Doubled Median Overall Survival versus Standard-of-Care Chemotherapy in Previously Treated Squamous Non-Small Cell Lung Cancer Patients

Verdict

Headline takes no side. We score BNTX +0.90 across three claims.

Our read: bullish.

BNTX score

+0.90

−1 bearish0bullish +1

More positive than 96% of ticker scores this week

Price reaction

NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.

What matters in this story